NasdaqGM - Delayed Quote • USD
CureVac N.V. (CVAC)
At close: April 26 at 4:00 PM EDT
Breakdown
TTM
12/31/2022
12/31/2021
12/31/2020
Total Revenue
42,880.0000
67,420.0000
102,990.0000
48,871.0000
Cost of Revenue
150,770.0000
183,993.0000
238,195.0000
14,173.0000
Gross Profit
-107,890.0000
-116,573.0000
-135,205.0000
34,698.0000
Operating Expense
201,248.0000
134,279.0000
277,058.0000
144,513.0000
Operating Income
-309,138.0000
-250,852.0000
-412,263.0000
-109,815.0000
Net Non Operating Interest Income Expense
5,472.0000
302.0000
-235.0000
-20,033.0000
Other Income Expense
1,436.0000
1,395.0000
--
--
Pretax Income
-302,231.0000
-249,155.0000
-412,498.0000
-129,848.0000
Tax Provision
67.0000
-126.0000
-782.0000
-726.0000
Net Income Common Stockholders
-302,298.0000
-249,029.0000
-411,716.0000
-129,122.0000
Diluted NI Available to Com Stockholders
-302,298.0000
-249,029.0000
-411,716.0000
-129,122.0000
Basic EPS
-1.47
-1.32
-2.21
-0.72
Diluted EPS
-1.47
-1.32
-2.21
-0.72
Basic Average Shares
212,895.9180
189,074.9110
186,012.5860
180,460.5650
Diluted Average Shares
212,895.9180
189,074.9110
186,012.5860
180,460.5650
Total Operating Income as Reported
-307,703.0000
-249,457.0000
-412,263.0000
-109,815.0000
Total Expenses
352,018.0000
318,272.0000
515,253.0000
158,686.0000
Net Income from Continuing & Discontinued Operation
-302,298.0000
-249,029.0000
-411,716.0000
-129,122.0000
Normalized Income
-303,518.6000
-250,423.2945
-411,716.0000
-129,122.0000
Interest Income
12,921.0000
4,009.0000
10,103.0000
2,070.0000
Interest Expense
7,449.0000
3,707.0000
10,338.0000
22,103.0000
Net Interest Income
5,472.0000
302.0000
-235.0000
-20,033.0000
EBIT
-294,782.0000
-245,448.0000
-402,160.0000
-107,745.0000
EBITDA
-276,991.0000
-221,707.0000
-386,486.0000
-97,074.0000
Reconciled Cost of Revenue
144,505.0000
171,948.0000
231,502.0000
9,620.0000
Reconciled Depreciation
17,791.0000
23,741.0000
15,674.0000
10,671.0000
Net Income from Continuing Operation Net Minority Interest
-302,298.0000
-249,029.0000
-411,716.0000
-129,122.0000
Total Unusual Items Excluding Goodwill
1,436.0000
1,395.0000
--
--
Total Unusual Items
1,436.0000
1,395.0000
--
--
Normalized EBITDA
-278,427.0000
-223,102.0000
-386,486.0000
-97,074.0000
Tax Rate for Calcs
0.0002
0.0000
0.0000
0.0000
Tax Effect of Unusual Items
215.4000
0.7055
--
--
12/31/2020 - 8/14/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
BNTX BioNTech SE
87.21
+0.58%
VIR Vir Biotechnology, Inc.
8.23
+7.86%
NVAX Novavax, Inc.
4.0900
+3.54%
ARCT Arcturus Therapeutics Holdings Inc.
26.55
+1.45%
DAWN Day One Biopharmaceuticals, Inc.
14.92
+12.94%
SAGE Sage Therapeutics, Inc.
13.69
+0.81%
BMRN BioMarin Pharmaceutical Inc.
80.91
-1.53%
SLRN Acelyrin, Inc.
4.2400
0.00%
VXRT Vaxart, Inc.
0.7097
+7.79%
VERV Verve Therapeutics, Inc.
6.16
-0.96%